Posts tagged Cory Kasimov


Clovis Oncology Inc (CLVS): Is the Pullback a Buying Opportunity?

J.P. Morgan dismantles investor concerns of liver toxicity, patient deaths, and “underwhelming” combo data.

Clovis Oncology Inc (CLVS) PARP Product Will Not Be Hit by AstraZeneca’s FDA Approval: J.P. Morgan

The FDA approved this morning a new indication for AstraZeneca’s (NYSE:AZN) ARP inhibitor Lynparza. The …

Puma Biotechnology Inc (PBYI): Positive Risk/Reward Ahead of ODAC Meeting

It is a good day to be a Puma Biotechnology Inc (NASDAQ:PBYI) investors, with shares …

Acorda Therapeutics Inc (ACOR) Faces Clear Setback With Unfavorable Ampyra Ruling

On Friday, Acorda Therapeutics Inc (NASDAQ:ACOR) was met with misfortune after a district judge invalidated …

J.P. Morgan Clips Price Target on Juno Therapeutics Inc (JUNO) Following Termination of JCAR015 Program

Juno Therapeutics Inc (NASDAQ:JUNO) shares are dropping 7% following the biotech firm’s official termination of …

J.P. Morgan Boosts Price Target for Clovis Oncology Inc (CLVS) on Back of Additional Pipeline Value

J.P. Morgan analyst Cory Kasimov is out with a new research report on shares of Neutral-rated Clovis …

Gilead Sciences, Inc. (GILD): Bictegravir HIV Data Looks Good

Gilead Sciences, Inc. (NASDAQ:GILD) announced yesterday positive phase 2 results for bictegravir vs. GSK/ViiV’s dolutegravir …

J.P. Morgan Provides Thoughts On Acorda Therapeutics Inc (ACOR)

Acorda Therapeutics Inc (NASDAQ:ACOR) shares rose 13% in Thursday’s trading session, after the drug maker announced …

Show More